Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT per Share : E£10.74 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EBIT per Share?

Egyptian International Pharmaceutical Investments's EBIT per Share for the three months ended in Dec. 2023 was E£2.38. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was E£10.74.

During the past 12 months, the average EBIT per Share Growth Rate of Egyptian International Pharmaceutical Investments was 48.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's EBIT per Share or its related term are showing as below:

CAI:PHAR's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.3
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Egyptian International Pharmaceutical Investments's EBIT for the three months ended in Dec. 2023 was E£353 Mil.

Egyptian International Pharmaceutical Investments EBIT per Share Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EBIT per Share Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

5.56

6.13

7.76

9.89

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															2.72	2.28	4.06	2.03	2.38

Egyptian International Pharmaceutical Investments EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Egyptian International Pharmaceutical Investments's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1471.78	/	148.756
=	9.89

Egyptian International Pharmaceutical Investments's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	353.26	/	148.756
=	2.37

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£10.74

Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Egyptian International Pharmaceutical Investments EBIT per Share Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.